XRTX logo

XORTX THERAPEUTICS INC

XRTXNASDAQ
🏆 #5213 by market capEarnings Nov 12US Equity
$1.09▲ $0.01 (+0.93%)
Market closed · at close
🔔
Track XRTX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.9%
7d▲ 15.3%
14d▼ 23.8%
30d▼ 36.3%
ytd▼ 64.6%
1y▼ 67.1%
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.06 – $1.09
52-Week Range
$0.83 – $3.65
Volume (shares)
577
Avg Volume (shares)
—
Shares Outstanding
1.8M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-0.4
P/S Ratio
0.0x
EPS (TTM)
$-2.32
Dividend Yield
0.00%
Dilution (1yr)
+114.2%
XRTX logo

XORTX THERAPEUTICS INC

XRTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▼ −17.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −24.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.3M▲ +114.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$827K▼ −$2M YoY
StockOtter · stockotter.space

About XORTX THERAPEUTICS INC

XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
5 analysts
Strong Buy1
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Mar 2024

Latest News & Updates

News unavailable.